Propofol Injectable Emulsion 10ML,20ML Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is defined in this product entry as a sterile, non-pyrogenic, oil-in-water emulsion containing propofol at a nominal concentration of 10 mg/mL. The two available single-dose presentations are 10 mL and 20 mL, corresponding to propofol contents of 100 mg and 200 mg per vial. The dispersed phase is composed of soybean oil 100 mg/mL with purified egg lecithin 12 mg/mL as emulsifier; the aqueous phase contains glycerol 22.5 mg/mL and sodium hydroxide for pH adjustment in Water for Injection. Some authorised presentations include disodium edetate 0.005% or sodium metabisulfite as an antimicrobial or antioxidant component, and final excipient composition must be verified against the specific marketing authorisation. The active substance is 2,6-diisopropylphenol, CAS 2078-54-8, molecular formula C12H18O, and nominal molecular weight 178.27 g/mol. At ambient temperature the bulk API is a slightly yellow oily liquid with very low aqueous solubility; intravenous administration therefore requires emulsification rather than direct aqueous dissolution. The product is isotonic, with measured osmolality near 300 mOsmol/kg, and is administered only by intravenous infusion or injection under continuous cardiorespiratory monitoring. The trade classification “pharma grade API for tablet/capsule/granule/injection, oral and injectable” identifies a broad raw-material distribution category; propofol is not established as an oral solid dosage form in regulatory labelling because of extensive first-pass hepatic metabolism and because the drug substance is an oily liquid at room temperature.

Does Emulsion Droplet Size Govern Batch-to-Batch Interchangeability?

Globule size distribution is the primary physical characteristic that separates acceptable propofol injectable emulsions from destabilised or pharmacokinetically inconsistent batches. The compendial framework for lipid injectable emulsions, USP <729>, requires that the mean droplet diameter remain below 500 nm and that the fraction of lipid globules larger than 5 µm, expressed as PFAT5, not exceed 0.05%. These limits are not cosmetic; large-droplet populations are associated with altered reticuloendothelial clearance, elevated risk of pulmonary fat embolism, and reduced physical stability during infusion pump administration. Batch release therefore routinely combines dynamic light scattering for the mean droplet size and light obscuration or laser diffraction for the large-droplet tail. Industrial manufacture of propofol emulsion typically involves rotor-stator pre-emulsification followed by high-pressure homogenization, with final globule size controlled by homogenization pressure, number of passes, and lipid-phase composition.

When a pharmacist or hospital purchaser evaluates 10 mL and 20 mL emulsions from different suppliers, globule size alone does not guarantee interchangeability. The lipid phase composition, the emulsifier source, the presence of disodium edetate or sulfite, and the homogenization equipment configuration all influence the zeta potential, the free drug concentration in the aqueous phase, and the rate of creaming. Two products may both satisfy USP <729> while differing in mean droplet size within the allowed range, for example one product at 180 nm and another at 320 nm. The clinical consequence of such variation is generally limited when the emulsion remains intact, but published data for formulation-specific differences in pain on injection and free propofol concentration are inconsistent. Therefore, the specification matrix below is not a marketing statement; it is the minimum release surface against which the product is evaluated before use.

Physical instability is not limited to improper manufacture. Freezing causes coalescence and phase separation in lipid emulsions, and the vial should be protected from freezing during transport and storage. Thermal stress above controlled room temperature accelerates droplet coalescence and increases free propofol concentration in the aqueous phase. The product should therefore be stored according to the registered label, typically at controlled room temperature, with protection from light. If the emulsion shows visible separation, large droplet accumulation, or colour change beyond the compendial description of a white to slightly off-white homogeneous emulsion, it must be discarded. Published data for this specific configuration remains limited with respect to long-term excursion beyond the registered storage range, and no claim of stability outside the label is made.

Microbiological risk is an operational boundary of equal weight to globule size. Propofol injectable emulsion supports microbial growth because the aqueous phase provides nutrients and the lipid phase can shield organisms from disinfectants. Even formulations containing disodium edetate 0.005% are not classified as preserved against extrinsic contamination under all conditions. Strict aseptic technique must be maintained during transfer, spiking, and administration. The vial is intended for single patient use; opened vials or lines are discarded within the time specified in authorised labelling, typically not more than 6 hours after opening. Dilution is permitted only with 5% dextrose injection, and admixture with other therapeutic agents is not recommended because electrolyte-containing diluents and many injectable drugs can destabilise the emulsion. The anaesthesiologist or intensivist is responsible for preventing inadvertent co-administration of incompatible injectables through the same line.

When the 20 mL Presentation Is Selected Over the 10 mL Vial

The 10 mL and 20 mL vials contain identical propofol concentration and identical emulsion vehicle; the difference is fill volume and total dose. Selection between presentations is therefore a workflow decision rather than a potency adjustment. For induction in a healthy adult at a weight-based dose of 1.5–2.5 mg/kg, a 10 mL vial containing 100 mg may be sufficient for a 40–60 kg patient, while a 20 mL vial containing 200 mg reduces the number of vial manipulations during maintenance infusion or when repeated induction is anticipated. In intensive care sedation, continuous infusion rates are commonly titrated within 5–50 µg/kg/min, and the larger presentation reduces container changes during prolonged delivery.

Neither presentation is suitable for oral administration. Propofol undergoes extensive hepatic first-pass metabolism, and the oral route would require formulation strategies that are not part of this emulsion product line. The granule, tablet, and capsule descriptors in the trade classification are therefore not interpreted as formulation instructions for propofol; they denote the broader pharmaceutical raw-material class to which the API may be assigned by certain distribution systems. Any request for oral propofol should be evaluated against regulatory filing data rather than this emulsion presentation.

Physicochemical Boundaries That Separate Propofol Emulsions From Non-Emulsified Injectable Systems

The defining technical advantage of the lipid emulsion is kinetic and thermodynamic rather than simply solubilisation. Propofol has a high octanol-water partition coefficient and a pKa near 11; in a purely aqueous solution the unionised drug would remain largely insoluble at physiological pH. Non-emulsified experimental propofol formulations using organic co-solvents or cyclodextrin vehicles have been investigated, but the clinical reference product class remains the soybean oil/egg lecithin emulsion. The emulsion reduces the free drug concentration in the aqueous phase, which influences the rate of drug transfer across vascular endothelium and may affect injection pain. However, propofol is highly protein-bound, approximately 97–98%, and its rapid distribution is governed more by blood flow and tissue partition than by the emulsifier composition alone.

Formulations using medium-chain triglycerides mixed with long-chain triglycerides alter the lipid-pharmacokinetic interface. The medium-chain triglyceride fraction is cleared more rapidly by hepatic and extrahepatic lipases, and comparative studies report differences in post-infusion triglyceride elevation and free propofol concentration, but published pharmacodynamic differences are not uniform across surgical populations. The product described here is differentiated from MCT/LCT propofol emulsions by its long-chain soybean oil vehicle and from fospropofol disodium by molecular identity; fospropofol is a water-soluble phosphate prodrug requiring enzymatic activation and is not equivalent to propofol injectable emulsion. Propofol emulsion is also distinct from benzodiazepine or barbiturate intravenous sedatives in mechanism, recovery profile, and critical risk of profound hypotension if administered too rapidly.

The emulsion is sensitive to high-shear mixing, air entrainment, and exposure to light. Accumulated air bubbles during transfer can generate coarse lipid aggregates and should be avoided. Concurrent administration with other lipid emulsions, such as parenteral nutrition, may alter total lipid load and should be accounted for in patients with impaired lipid clearance. The product is not intended for intrathecal or epidural administration, and the manufacturer’s control strategy does not include tests for that route. In paediatric and geriatric use, dose adjustment is necessary, and the vial size should be matched to the required dose to minimise the interval between opening and completion of administration. Published batch-to-batch variance for high-pressure homogenized propofol emulsions is small when the mean droplet size and PFAT5 are held within the compendial envelope; deviations beyond that envelope are not accepted by release testing, and the material is rejected before distribution.